


CLAIMS

1. A compound of Formula (VIII):



wherein

X^1 is O, NH, S, CH_2 , or CF_2 ;

R^1 and R^2 are independently selected from hydrogen, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^3 is selected from hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, and nitro;

n is a number from zero to 4;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and $-NR^{22}R^{23}$;

wherein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and

each R^{22} and R^{23} are independently selected from hydrogen and C_{1-6} alkyl or R^{22} and R^{23} may be joined to form a 3 to 10 membered ring;

R^5 is selected from hydrogen and C_{1-6} alkyl;

R^6 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^7 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^8 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

Q is CR^9 or N;


where R^9 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^{11} is selected from hydrogen and C_{1-6} alkyl;

R^{12} is selected from hydrogen and C_{1-6} alkyl;

R^{13} is selected from hydrogen, C_{1-6} alkyl, C_{1-6} acyl, SO_2 - C_{1-6} alkyl, C_{3-7} cycloalkyl, and C_{6-20} aryl,

wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C_{1-6} alkoxy, or halo; and



wherein R^{10} is selected from hydrogen and C_{1-6} alkyl;


R^{15} is unsubstituted methyl, or is C_{2-4} alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and


m is 1 or 2; or is

(b) where R^{19} and R^9 taken together form a 5- or 6-membered heteroaryl ring optionally substituted with C_{1-6} alkyl that is unsubstituted or substituted with amino, hydroxyl, or halo; and R^{18} is hydrogen or C_{1-6} alkyl, or is absent to satisfy valency of the heteroaryl ring;

provided that neither of R^6 or R^7 is methoxy when $-NR^{18}R^{19}$ is $R^{10}-N \begin{array}{c} \diagup \quad \diagdown \\ \text{---} \quad \text{---} \\ \diagdown \quad \diagup \end{array} N-\xi$;
or a pharmaceutically acceptable salt thereof.

2. A compound of Formula (Ia) or (Ib):





wherein

R^1 and R^2 are independently selected from hydrogen, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^3 is selected from hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, and nitro;

n is a number from zero to 4;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and $-NR^{22}R^{23}$;

wherein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and

each R^{22} and R^{23} are independently selected from hydrogen and C_{1-6} alkyl or R^{22} and R^{23} may be joined to form a 3 to 10 membered ring;

R^5 is selected from hydrogen and C_{1-6} alkyl;

R^6 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^7 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^8 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

Q is CR^9 or N ;

where R^9 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^{10} is selected from hydrogen and C_{1-6} alkyl;

a is one or two;

Ring A is an aromatic ring;

R^{20} and R^{21} are independently selected from hydrogen and C_{1-6} alkyl; wherein alkyl is unsubstituted or substituted with amino, hydroxyl, or halo; wherein R^{21} may be absent as needed to satisfy valency;


R^{11} is selected from hydrogen and C_{1-6} alkyl;

R^{12} is selected from hydrogen and C_{1-6} alkyl; and

R^{13} is selected from hydrogen, C_{1-6} alkyl, C_{1-6} acyl, SO_2 - C_{1-6} alkyl, C_{3-7} cycloalkyl, and C_{6-20} aryl,

wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C_{1-6} alkoxy, or halo;
or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is a compound of Formula (II):



wherein

R^1 and R^2 are independently selected from hydrogen, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^3 is selected from hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, and nitro;

n is a number from zero to 4;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and $-NR^{22}R^{23}$;

wherein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and

each R^{22} and R^{23} are independently selected from hydrogen and C_{1-6} alkyl or R^{22} and R^{23} may be joined to form a 3 to 10 membered ring;

R^5 is selected from hydrogen and C_{1-6} alkyl;

R^6 is selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R⁷ is selected from hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkoxy, C₁₋₆ haloalkoxy, hydroxyl, cyano, and nitro;

R⁸ is selected from hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, hydroxyl, cyano, and nitro;

Q is CR⁹ or N;

where R⁹ is selected from hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, hydroxyl, cyano, and nitro;


R¹⁰ is selected from hydrogen and C₁₋₆ alkyl;

R¹¹ is selected from hydrogen and C₁₋₆ alkyl;

R¹² is selected from hydrogen and C₁₋₆ alkyl; and



R¹³ is selected from hydrogen, C₁₋₆ alkyl, and C₆₋₂₀ aryl, wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C₁₋₆ alkoxy, or halo;
or a pharmaceutically acceptable salt thereof.






4. The compound of claim 1, wherein X¹ is O or NH.
5. The compound of any one of claims 1-4, wherein R¹¹ is hydrogen.
6. The compound of any one of claims 1-5, wherein R¹² is hydrogen.
7. The compound of any one of claims 1-6, wherein R¹ and R² are each hydrogen.
8. The compound of any one of claims 1-7, wherein n is zero.

9. The compound of claim 1, wherein -NR¹⁸R¹⁹ is 

10. The compound of claim 9, wherein R¹⁰ is methyl.
11. The compound of any one of claims 1-10, wherein R¹³ is hydrogen.
12. The compound of any one of claims 1-10, wherein R¹³ is C₁₋₆alkyl substituted with hydroxyl or halo.

13. The compound of any one of claims 1-12, wherein R⁶ is hydrogen.
14. The compound of any one of claims 1-13, wherein R⁷ is hydrogen or methoxy.
15. The compound of any one of claims 1-14, wherein R⁸ is hydrogen.
16. The compound of any one of claims 1-15, wherein Q is N.
17. The compound of any one of claims 1-15, wherein Q is CR⁹.
18. The compound of claim 17, wherein R⁹ is hydrogen or fluoro.
19. The compound of claim 1, wherein R¹⁹ and R⁹ together form a 5- or 6-membered ring optionally substituted with C₁₋₆alkyl that is unsubstituted or substituted with amino.
20. A compound selected from the group consisting of:






	<p>N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>






	N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
	N-(3-((7-(hydroxymethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
	N-(3-((7-(hydroxymethyl)-2-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
	N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
	N-(3-((7-(2-fluoroethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide

	<p>N-(3-((2-((1-(2-(dimethylamino)ethyl)-1H-indol-5-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((2-((dimethylamino)methyl)quinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-cyclopropyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-cyclopropyl-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>

	<p>N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(2-hydroxyethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(2-hydroxyethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-((dimethylamino)methyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-((dimethylamino)methyl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>

	<p>N-(3-((5-(dimethylamino)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(dimethylamino)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(2-(dimethylamino)ethyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(2-(dimethylamino)ethyl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(aziridin-1-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>


	<p>N-(3-((5-(aziridin-1-yl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(azetidin-1-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((5-(azetidin-1-yl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>

	<p>N-(3-((7-cyclopropyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((7-cyclopropyl-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-((7-acetyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>

	<p>N-(3-((7-acetyl-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-(2-(4-(1-(2-fluoroethyl)azetidin-3-ylamino)-2-methoxyphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
	<p>N-(3-(2-(4-(1-(2-fluoroethyl)azetidin-3-ylamino)-2-methoxyphenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)acrylamide; and</p>
	<p>N-(3-((2-((2-(piperidin-1-ylmethyl)quinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>

and pharmaceutically acceptable salts thereof.

21. The compound of claim 1, wherein the compound is a compound of Formula (VII):



wherein

R¹ and R² are independently selected from hydrogen, halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

R⁸ is selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, hydroxyl, cyano, and nitro;

R¹⁰ is C₁₋₆ alkyl; and

R¹³ is hydrogen or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 21, wherein R¹ and R² are each hydrogen.
23. The compound of claims 21 or 22, wherein R⁸ is halo.
24. The compound of claim 23, wherein R⁸ is fluoro.
25. The compound of any one of claims 21-24, wherein R¹⁰ is methyl, ethyl, or isopropyl.
26. The compound of claim 25, wherein R¹⁰ is methyl.
27. The compound of any one of claims 21-26, wherein R¹³ is hydrogen.
28. A pharmaceutical composition comprising (a) at least one compound of any of claims 1-27 or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier or excipient.

29. The compound of any of claims 1-27 or a pharmaceutically acceptable salt thereof, for use in a method of treating and/or preventing a proliferation disorder, cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, wherein said compound or pharmaceutically acceptable salt thereof is for administering in an effective amount to a subject in need of such treatment.

30. The compound N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide or a pharmaceutically acceptable salt thereof.

31. The compound of claim 30, wherein the compound is N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide hydrochloride salt or maleate salt.

32. The pharmaceutical composition of claim 28, wherein the pharmaceutically acceptable salt is a HCl salt, a maleate salt, a HBr salt, a hydroxybutanedioic acid salt or a fumaric acid salt.

33. The compound of claim 29, wherein the pharmaceutically acceptable salt is a HCl salt, a maleate salt, a HBr salt, a hydroxybutanedioic acid salt or a fumaric acid salt.

34. Use of a compound of any of claims 1-27, 30 and 31, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating and/or preventing a disease or disorder selected from the group consisting of sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head and neck cancers, pancreatic cancer, arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related disease, psoriasis, dry eye, eczema, dermatitis, atopic dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratory distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction, congestive heart failure,

cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmunity thyroid disease, urticaria (cnidosis), multiple sclerosis, scleroderma, organ transplantation rejection, heteroplastic graft, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, diabetic associated diseases, inflammation, pelvic inflammatory disease, allergic rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma, follicular lymphoma, allotransplantation, Graft versus host disease, and autoimmune diabetes~~a proliferation disorder, cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease.~~

35. Use according to claim 34, wherein the ~~proliferation disease or~~ disorder is selected from the group consisting of sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non- small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head and neck cancers, and pancreatic cancer.

36. A combination for use in treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject, which combination comprises an effective amount of a compound of any of claims 1-27, 30 and 31, or a pharmaceutically acceptable salt thereof, and an effective amount of a second prophylactic or therapeutic agent for treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject.

37. The combination of claim 36 for use in a method for treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject, wherein said combination is for administering in an effective amount to a subject in need thereof.

38. The use of claim 34, further comprising an effective amount of a second prophylactic or therapeutic agent.